Accès gratuit
Numéro
Med Sci (Paris)
Volume 27, Numéro 10, Octobre 2011
Page(s) 842 - 849
Section M/S Revues
DOI https://doi.org/10.1051/medsci/20112710012
Publié en ligne 21 octobre 2011
  1. Schwartz RH. Costimulation of T lymphocytes: the role of CD28, CTLA-4, and B7/BB1 in interleukin-2 production and immunotherapy. Cell 1992 ; 71 : 1065–1068. [CrossRef] [PubMed]
  2. Linsley PS, Ledbetter JA. The role of the CD28 receptor during T cell responses to antigen. Annu Rev Immunol 1993 ; 11 : 191–212. [CrossRef] [PubMed]
  3. Thompson CB, Lindsten T, Ledbetter JA, et al. CD28 activation pathway regulates the production of multiple T-cell-derived lymphokines/cytokines. Proc Natl Acad Sci USA 1989 ; 86 : 1333–1337. [CrossRef]
  4. Linsley PS, Brady W, Grosmaire L, et al. Binding of the B cell activation antigen B7 to CD28 costimulates T cell proliferation and interleukin 2 mRNA accumulation. J Exp Med 1991 ; 173 : 721–730. [CrossRef] [PubMed]
  5. Cerdan C, Martin Y, Courcoul M, et al. CD28 costimulation up-regulates long-term IL-2R beta expression in human T cells through combined transcriptional and post-transcriptional regulation. J Immunol 1995 ; 154 : 1007–1013. [PubMed]
  6. Boise LH, Minn AJ, Noel PJ, et al. CD28 costimulation can promote T cell survival by enhancing the expression of Bcl-XL. Immunity 1995 ; 3 : 87–98. [CrossRef] [PubMed]
  7. Tacke M, Hanke G, Hanke T, Hunig T. CD28-mediated induction of proliferation in resting T cells in vitro and in vivo without engagement of the T cell receptor: evidence for functionally distinct forms of CD28. Eur J Immunol 1997 ; 27 : 239–247. [CrossRef] [PubMed]
  8. Fraser JD, Irving BA, Crabtree GR, Weiss A. Regulation of interleukin-2 gene enhancer activity by the T cell accessory molecule CD28. Science 1991 ; 251 : 313–316. [CrossRef] [PubMed]
  9. Granelli-Piperno A, Nolan P. Nuclear transcription factors that bind to elements of the IL-2 promoter. Induction requirements in primary human T cells. J Immunol 1991 ; 147 : 2734–2739. [PubMed]
  10. Pages F, Ragueneau M, Rottapel R, et al. Binding of phosphatidylinositol-3-OH kinase to CD28 is required for T-cell signalling. Nature 1994 ; 369 : 327–329. [CrossRef] [PubMed]
  11. Rudd CE, Taylor A, Schneider H. CD28 and CTLA-4 coreceptor expression and signal transduction. Immunol Rev 2009 ; 229 : 12–26. [CrossRef] [PubMed]
  12. Sanchez-Lockhart M, Marin E, Graf B, et al. Cutting edge: CD28-mediated transcriptional and posttranscriptional regulation of IL-2 expression are controlled through different signaling pathways. J Immunol 2004 ; 173 : 7120–7124. [PubMed]
  13. Miller J, Baker C, Cook K, et al. Two pathways of costimulation through CD28. Immunol Res 2009 ; 13 février (online).
  14. Huang J, Lo PF, Zal T, et al. CD28 plays a critical role in the segregation of PKC theta within the immunologic synapse. Proc Natl Acad Sci USA 2002 ; 99 : 9369–9373. [CrossRef]
  15. Saito T, Yokosuka T, Hashimoto-Tane A. Dynamic regulation of T cell activation and co-stimulation through TCR-microclusters. FEBS Lett 2010 ; 584 : 4865–4871. [CrossRef] [PubMed]
  16. Linsley PS, Golstein P. Lymphocyte activation: T-cell regulation by CTLA-4. Curr Biol 1996 ; 6 : 398–400. [CrossRef] [PubMed]
  17. PeachRJ, Bajorath J, Brady W, et al. Complementarity determining region 1 (CDR1)- and CDR3-analogous regions in CTLA-4 and CD28 determine the binding to B7-1. J Exp Med 1994 ; 180 : 2049–2058. [CrossRef] [PubMed]
  18. Truneh A, Reddy M, Ryan P, et al. Differential recognition by CD28 of its cognate counter receptors CD80 (B7.1) and B70 (B7.2): analysis by site directed mutagenesis. Mol Immunol 1996 ; 33 : 321–334. [CrossRef] [PubMed]
  19. Van der Merwe PA, Bodian DL, Daenke S, et al. CD80 (B7-1) binds both CD28 and CTLA-4 with a low affinity and very fast kinetics. J Exp Med 1997 ; 185 : 393–403. [CrossRef] [PubMed]
  20. Laurent S, Carrega P, Saverino D, et al. CTLA-4 is expressed by human monocyte-derived dendritic cells and regulates their functions. Hum Immunol 2010 ; 71 : 934–941. [CrossRef] [PubMed]
  21. Tivol EA, Borriello F, Schweitzer AN, et al. Loss of CTLA-4 leads to massive lymphoproliferation and fatal multiorgan tissue destruction, revealing a critical negative regulatory role of CTLA-4. Immunity 1995 ; 3 : 541–547. [CrossRef] [PubMed]
  22. Waterhouse P, Penninger JM, Timms E, et al. Lymphoproliferative disorders with early lethality in mice deficient in Ctla-4. Science 1995 ; 270 : 985–988. [CrossRef] [PubMed]
  23. Walunas TL, Lenschow DJ, Bakker CY, et al. CTLA-4 can function as a negative regulator of T cell activation. Immunity 1994 ; 1 : 405–413. [CrossRef] [PubMed]
  24. Pedicord VA, Montalvo W, Leiner IM, Allison JP. Single dose of anti-CTLA-4 enhances CD8+ T-cell memory formation, function, and maintenance. Proc Natl Acad Sci USA 2010 ; 108 : 266–271. [CrossRef]
  25. Jain N, Nguyen H, Chambers C, Kang J. Dual function of CTLA-4 in regulatory T cells and conventional T cells to prevent multiorgan autoimmunity. Proc Natl Acad Sci USA 2010 ; 107 : 1524–1528. [CrossRef]
  26. Ise W, Kohyama M, Nutsch KM, et al. CTLA-4 suppresses the pathogenicity of self antigen-specific T cells by cell-intrinsic and cell-extrinsic mechanisms. Nat Immunol 2010 ; 11 : 129–135. [CrossRef] [PubMed]
  27. Dustin ML. Insights into function of the immunological synapse from studies with supported planar bilayers. Curr Top Microbiol Immunol 2010 ; 340 : 1–24. [CrossRef] [PubMed]
  28. Yokosuka T, Kobayashi W, Sakata-Sogawa K, et al. Spatiotemporal regulation of T cell costimulation by TCR-CD28 microclusters and protein kinase C theta translocation. Immunity 2008 ; 29 : 589–601. [CrossRef] [PubMed]
  29. Yokosuka T, Kobayashi W, Takamatsu M, et al. Spatiotemporal basis of CTLA-4 costimulatory molecule-mediated negative regulation of T cell activation. Immunity 2010 ; 33 : 326–339. [CrossRef] [PubMed]
  30. Curran MA, Montalvo W, Yagita H, Allison JP. PD-1 and CTLA-4 combination blockade expands infiltrating T cells and reduces regulatory T and myeloid cells within B16 melanoma tumors. Proc Natl Acad Sci USA 2010 ; 107 : 4275–4280. [CrossRef]
  31. Van Elsas A, Hurwitz AA, Allison JP. Combination immunotherapy of B16 melanoma using anti-cytotoxic T lymphocyte-associated antigen 4 (CTLA-4) and granulocyte/macrophage colony-stimulating factor (GM-CSF)-producing vaccines induces rejection of subcutaneous and metastatic tumors accompanied by autoimmune depigmentation. J Exp Med 1999 ; 190 : 355–366. [CrossRef] [PubMed]
  32. Sharpe AH. Mechanisms of costimulation. Immunol Rev 2009 ; 229 : 5–11. [CrossRef] [PubMed]
  33. Olive D. Corécepteurs lymphocytaires. Med Sci (Paris) 2006 ; 22 : 1069–1074. [CrossRef] [EDP Sciences] [PubMed]
  34. Watanabe N, Gavrieli M, Sedy JR, et al. BTLA is a lymphocyte inhibitory receptor with similarities to CTLA-4 and PD-1. Nat Immunol 2003 ; 4 : 670–679. [CrossRef] [PubMed]
  35. Serriari NE, Gondois-Rey F, Guillaume Y, et al. B and T lymphocyte attenuator is highly expressed on CMV-specific T cells during infection and regulates their function. J Immunol 2010 ; 185 : 3140–3148. [CrossRef] [PubMed]
  36. Weber J. Review: anti-CTLA-4 antibody ipilimumab: case studies of clinical response and immune-related adverse events. Oncologist 2007 ; 12 : 864–872. [CrossRef] [PubMed]
  37. Robert C, Matteus C. Anticorps anti-CTLA-4 : une avancée thérapeutique majeure dans le traitement du mélanome métastatique. Med Sci (Paris) 2011 ; 27 : 850–858. [CrossRef] [EDP Sciences] [PubMed]

Les statistiques affichées correspondent au cumul d'une part des vues des résumés de l'article et d'autre part des vues et téléchargements de l'article plein-texte (PDF, Full-HTML, ePub... selon les formats disponibles) sur la platefome Vision4Press.

Les statistiques sont disponibles avec un délai de 48 à 96 heures et sont mises à jour quotidiennement en semaine.

Le chargement des statistiques peut être long.